VIRVir Biotechnology Inc
VIR
Vir Biotechnology Inc6,306
Mkt Cap
$712.64MVolume
1.69M52W High
$14.4552W Low
$4.16PE Ratio
-1.42VIR Fundamentals
Price
$5.23Prev Close
$5.12Open
$5.1150D MA
$5.54Beta
1.49Avg. Volume
1.5MEPS (Annual)
-$3.83P/B
0.90Rev/Employee
$181,875.00Vir Biotechnology Stock Set For Premarket Surge? Retail Trader Hopes Swell As ‘Phenomenal’ HDV Data Sets Stage For Gilead Showdown
Phase 2 trial showed 66% of patients achieved undetectable hepatitis delta virus RNA with Vir’s tobevibart-elebsiran combo, with no serious safety issues reported.
Vir Biotechnology Announces AASLD The Liver Meeting Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Companys Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants...
Business Wire·3h ago
Insider Selling: Vir Biotechnology (NASDAQ:VIR) EVP Sells 2,385 Shares of Stock
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) EVP Verneuil Vanina De sold 2,385 shares of the company's stock in a transaction dated Wednesday, November 5th. The shares were sold at an...
MarketBeat·1d ago
Vir Biotechnology to Participate in the Jefferies 2025 London Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the Jefferies 2025 London Healthcare Conference on Tuesday...
Business Wire·2d ago
Vir Biotechnology (NASDAQ:VIR) Releases Quarterly Earnings Results, Misses Expectations By $0.47 EPS
Vir Biotechnology (NASDAQ:VIR - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of...
MarketBeat·3d ago
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -67.14% and -96.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View
GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.
Zacks·11d ago
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2025 Financial Results on November 5, 2025
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2025, on November 5...
Business Wire·18d ago
Vir Biotechnology Announces First Patient Dosed in Part 3 of Phase 1 Trial of PSMA-Targeting PRO-XTEN Dual-Masked T-Cell Engager VIR-5500 in Combination with Androgen Receptor Pathway Inhibitors for the Treatment of Metastatic Prostate Cancer
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the first patient has been dosed in Part 3 of the Companys Phase 1 clinical trial evaluating VIR-5500 in combination with androgen receptor...
Business Wire·1mo ago
Vir Biotechnology (VIR) Surges 6.9%: Is This an Indication of Further Gains?
Vir Biotechnology (VIR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·1mo ago